Eli Lilly and Company

Jared Harris Linebarger

Ying Kwong Yee

Charles David Jones

Sunil Nagpal

Robert Peter Gajewski

Tianwei Ma

Jianliang Lu

Michael Robert Wiley

Gerald Floyd Smith

John Joseph Masters

David Kent Herron

David Mendel

Jeffry Bernard Franciskovich

Leland O Weigel

Leander Merritt

Ryan Edward Stites

Andrew Michael Ratz

Angela Lynn Marquart

Karl Robert Dahnke

Emilio Enrique Bunel

Todd Parker Simard

The present invention relates to novel, non-secosteroidal, sulfonate and sulfonamide functional diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&#x3b1;,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Vitamin D receptor modulators

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I). 

Antithrombotic ethers

The present invention relates to novel, non-secosteroidal, phenyl-thiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&#x3b1;,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Phenyl-thiophene type vitamin D receptor modulators

Growing community of inventors

Indianapolis, IN, United States of America

Jared Harris Linebarger